A Comparative Study between Dexmedetomidine and Midazolam as an adjuvant to intrathecal Bupivacaine

Dr. K.K. Arora; Dr. Neetu Gupta; Dr. Nidhi Sharma

Volume : IX, Issue : VIII, August - 2020

A Comparative Study between Dexmedetomidine and Midazolam as an adjuvant to intrathecal Bupivacaine

Dr. K. K. Arora, Dr. Neetu Gupta, Dr. Nidhi Sharma

Abstract :

Background: Subarachnoid block(SAB) is the common mode of anaesthesia. To prolong its action various adjuvants are being added to local anaesthetics(LA). In this study we compared the efficacy and safety of midazolam and dexmedetomidine as an adjuvant to intrathecal 0.5% hyperbaric (H) bupivacaine. Material & Methods: 80 ASA grade I or II patients of either sex scheduled for lower limb or lower abdominal surgeries were randomly allocated into two groups, Group D & Group M. In group D, patients received 3ml of 0.5% (H) bupivacaine + dexmedetomidine 5mcg in 0.5ml normal saline(NS). While group M received 3ml of 0.5% (H) bupivacaine + 2mg midazolam ( 0.4ml of 5mg/ml) + 0.1ml of NS. Onset of sensory & motor block and duration of sensory & motor block were recorded. Patients were monitored for any haemodynamic changes and side effect. Result: Duration of both sensory & motor blockade was significantly prolonged in group D as compared to group M. There was no clinically significant difference observed among both the groups in respect to hemodynamic parameters, sedation and side effect. Conclusion: Dexmedetomidine as an adjuvant to intrathecal bupivacaine (H) was better as compared to midazolam. It significantly prolongs the duration of analgesia postoperatively without any significant side effect.